Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

被引：0
|
作者：
Leonie JM Mekenkamp
Jolien Tol
Jeroen R Dijkstra
Inge de Krijger
M Elisa Vink-Börger
Shannon van Vliet
Steven Teerenstra
Eveline Kamping
Eugène Verwiel
Miriam Koopman
Gerrit A Meijer
J Han JM van Krieken
Roland Kuiper
Cornelis JA Punt
Iris D Nagtegaal
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Medical Oncology
[2] Radboud University Nijmegen Medical Centre,Department of Pathology
[3] Radboud University Nijmegen Medical Centre,Department of Epidemiology, Biostatistics and Health Technology Assessment
[4] Radboud University Nijmegen Medical Centre,Department of Human Genetics
[5] University Medical Center Utrecht,Department of Medical Oncology
[6] VU University Medical Center,Department of Pathology
[7] University of Amsterdam,Department of Medical Oncology, Academic Medical Centre
来源：
BMC Cancer | / 12卷
关键词：
Cetuximab; KRAS Mutation; Copy Number Change; Poor Responder; Copy Number Gain;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
    Zaccarelli, Eeonora
    Tomao, Silverio
    Codacci-Pisanelli, Giovanni
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (06): : 565 - 566
  • [42] Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab plus Irinotecan
    Bando, Hideaki
    Yoshino, Takayuki
    Yuki, Satoshi
    Shinozaki, Eiji
    Nishina, Tomohiro
    Kadowaki, Shigenori
    Yamazaki, Kentaro
    Kajiura, Shinya
    Tsuchihara, Katsuya
    Fujii, Satoshi
    Yamanaka, Takeharu
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (12) : 1146 - 1151
  • [43] The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011
    Lievre, A.
    Artru, P.
    Guiu, M.
    Laurent-Puig, P.
    Merlin, J. L.
    Sabourin, J. C.
    Viguier, J.
    Bastie, A.
    Seronde, A.
    Ducreux, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) : 2126 - 2133
  • [44] The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
    Daeyoun David Won
    Jae Im Lee
    In Kyu Lee
    Seong-Taek Oh
    Eun Sun Jung
    Sung Hak Lee
    BMC Cancer, 17
  • [45] KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients
    Avadanei, Elena-Roxana
    Caruntu, Irina-Draga
    Nuca, Irina
    Balan, Raluca Anca
    Lozneanu, Ludmila
    Giusca, Simona-Eliza
    Pricope, Diana Lavinia
    Dascalu, Cristina Gena
    Amalinei, Cornelia
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2025, 47 (02)
  • [46] Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
    Huang, Chi-Jung
    Huang, Shih-Hung
    Chien, Chih-Cheng
    Lee, Henry Hsin-Chung
    Yang, Shung-Haur
    Chang, Chun-Chao
    Lee, Chia-Long
    ONCOLOGY LETTERS, 2016, 12 (06) : 4427 - 4434
  • [47] The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status
    Akman, Tulay
    Oztop, Ilhan
    Baskin, Yasemin
    Unek, Ilkay Tugba
    Demir, Necla
    Ellidokuz, Hulya
    Yilmaz, Ahmet Ugur
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 96 - 102
  • [48] Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib
    Juergensmeier, J. M.
    Hoff, P. M.
    Pike, L.
    Robertson, J. D.
    Morgan, S.
    McWalter, G.
    Wilson, D.
    Smith, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
    Won, Daeyoun David
    Lee, Jae Im
    Lee, In Kyu
    Oh, Seong-Taek
    Jung, Eun Sun
    Lee, Sung Hak
    BMC CANCER, 2017, 17
  • [50] Overall survival according to mutation frequency of BRAF, NRAS genes, and MSI status in patients with wild-type KRAS metastatic colorectal cancer treated with cetuximab
    Santos, F.
    Reis, R.
    Barroti, L.
    Datorre, J.
    Pereira, A.
    Carvalho, A.
    Berardinelli, G.
    Araujo, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S185 - S185
12345